(Photo courtesy washingtonpost.com)
Gilead Sciences said its coronavirus treatment, remdesivir, will cost $3,120 for a typical US patient with private insurance.
- Governments will get a discount —$2,340 for the standard five-day course.
Remdesivir is the first drug shown to be effective against the coronavirus. A clinical trial showed that the drug reduced COVID-19 patients’ recovery times by four days …but it hasn’t been proven to reduce mortality.
Gilead stands by the price tag, saying $3,120 is “well below” the value of remdesivir. “As with many aspects of this pandemic, we are in uncharted territory in pricing remdesivir,” Gilead CEO Daniel O’Day said. “As the world continues to reel from the human, social and economic impact of this pandemic, we believe that pricing remdesivir well below value is the right and responsible thing to do.”
Rep. Lloyd Doggett, a Democrat from Texas who serves as the chair of the House Ways and Means Health Subcommittee, disagrees. He slammed the pricing of the drug as “outrageous” for a “very modest drug.”
he company will start charging patients next month—but don’t panic. “Whether you’re covered by a private insurer, a government insurer, or you’re uninsured with Covid-19, there will not be an issue for access with remdesivir,” O’Day said. Uninsured individuals will be covered under the CARES Act. For privately insured people, out-of-pocket costs will be determined by individual insurance plans.